Shanghai, China

Xishan Xiong

This inventor holds 1 USPTO granted patent. Top assignee: Shanghai Institute of Materia Medica, Cas. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xishan Xiong. Retrieved from https://idiyas.com/inventor/xishan-xiong

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xishan Xiong: Innovator in Pharmaceutical Chemistry

Introduction

Xishan Xiong is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that have therapeutic potential.

Latest Patents

Xishan Xiong holds a patent for "Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists." This invention discloses compounds of Structural Formula (I), including enantiomers, racemic bodies, pharmaceutically acceptable salts, solvates, or hydrates. The compounds are designed to activate PPAR-RXR heterodimers, which interact with specific DNA response elements within the promoter regions of target genes. This innovation is particularly relevant for the treatment and prevention of polycystic kidney disease and cancer.

Career Highlights

Xishan Xiong is affiliated with the Shanghai Institute of Materia Medica, where he conducts research and development in medicinal chemistry. His work focuses on creating novel compounds that can lead to effective treatments for various diseases.

Collaborations

Xishan collaborates with esteemed colleagues such as Jianhua Shen and Changlin Mei, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Xishan Xiong's work exemplifies the intersection of innovation and pharmaceutical research. His contributions to the development of PPAR agonists highlight the potential for new therapeutic strategies in treating complex diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…